Liraglutide in clinical practice: Glycemic control, and predictors of good response

Lecube, Albert; Gonzalez, Cyntia; Morales, Cristóbal

doi:10.1016/j.medcle.2015.10.005

array:24 ["pii" => "S2387020616303357" "issn" => "23870206" "doi" => "10.1016/j.medcle.2015.10.005" "estado" => "S300" "fechaPublicacion" => "2016-05-06" "aid" => "3429" "copyright" => "Elsevier España, S.L.U.. All rights reserved" "copyrightAnyo" => "2015" "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "crp" "cita" => "Med Clin. 2016;146:415-6" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "Traduccion" => array:1 [ "en" => array:19 [ "pii" => "S0025775315005941" "issn" => "00257753" "doi" => "10.1016/j.medcli.2015.10.020" "estado" => "S300" "fechaPublicacion" => "2016-05-06" "aid" => "3429" "copyright" => "Elsevier España, S.L.U." "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "crp" "cita" => "Med Clin. 2016;146:415-6" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:2 [ "total" => 25 "formatos" => array:2 [ "HTML" => 17 "PDF" => 8 ] ] "en" => array:10 [ "idiomaDefecto" => true "cabecera" => "Scientific letter" "titulo" => "Liraglutide in clinical practice: Glycemic control, and predictors of good response" "tienePdf" => "en" "tieneTextoCompleto" => "en" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "415" "paginaFinal" => "416" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Liraglutide en la práctica clínica: control glucémico y predictores de buena respuesta" ] ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Albert Lecube, Cyntia Gonzalez, Cristóbal Morales" "autores" => array:3 [ 0 => array:2 [ "nombre" => "Albert" "apellidos" => "Lecube" ] 1 => array:2 [ "nombre" => "Cyntia" "apellidos" => "Gonzalez" ] 2 => array:2 [ "nombre" => "Cristóbal" "apellidos" => "Morales" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "en" => array:9 [ "pii" => "S2387020616303357" "doi" => "10.1016/j.medcle.2015.10.005" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2387020616303357?idApp=UINPBA00004N" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0025775315005941?idApp=UINPBA00004N" "url" => "/00257753/0000014600000009/v1_201604180002/S0025775315005941/v1_201604180002/en/main.assets" ] ] "itemSiguiente" => array:19 [ "pii" => "S2387020616303394" "issn" => "23870206" "doi" => "10.1016/j.medcle.2016.06.021" "estado" => "S300" "fechaPublicacion" => "2016-05-06" "aid" => "3396" "copyright" => "Elsevier España, S.L.U." "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "crp" "cita" => "Med Clin. 2016;146:416-7" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "en" => array:10 [ "idiomaDefecto" => true "cabecera" => "Scientific letter" "titulo" => "Hyperparathyroidism in multiple endocrine neoplasia type 2A syndrome. Surgical and genetic implications" "tienePdf" => "en" "tieneTextoCompleto" => "en" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "416" "paginaFinal" => "417" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Hiperparatiroidismo en el síndrome de neoplasia endocrina múltiple tipo 2A. Implicaciones terapéuticas y genéticas" ] ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Beatriz Febrero, José M. Rodríguez, Antonio Ríos, Pascual Parrilla" "autores" => array:4 [ 0 => array:2 [ "nombre" => "Beatriz" "apellidos" => "Febrero" ] 1 => array:2 [ "nombre" => "José M." "apellidos" => "Rodríguez" ] 2 => array:2 [ "nombre" => "Antonio" "apellidos" => "Ríos" ] 3 => array:2 [ "nombre" => "Pascual" "apellidos" => "Parrilla" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "S0025775315005254" "doi" => "10.1016/j.medcli.2015.10.002" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0025775315005254?idApp=UINPBA00004N" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2387020616303394?idApp=UINPBA00004N" "url" => "/23870206/0000014600000009/v1_201609081639/S2387020616303394/v1_201609081639/en/main.assets" ] "itemAnterior" => array:19 [ "pii" => "S2387020616303370" "issn" => "23870206" "doi" => "10.1016/j.medcle.2016.06.019" "estado" => "S300" "fechaPublicacion" => "2016-05-06" "aid" => "3385" "copyright" => "Elsevier España, S.L.U." "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "crp" "cita" => "Med Clin. 2016;146:414-5" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "en" => array:10 [ "idiomaDefecto" => true "cabecera" => "Scientific letter" "titulo" => "Euthyroid sick syndrome as a risk factor for mortality in critically ill patients" "tienePdf" => "en" "tieneTextoCompleto" => "en" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "414" "paginaFinal" => "415" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Síndrome del enfermo eutiroideo como factor de riesgo para mortalidad en el paciente crítico" ] ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Maria del Rosario Muñoz-Ramirez, Claudia Alejandra Ortega-Valdez, Eduardo Murillo-Heredia" "autores" => array:3 [ 0 => array:2 [ "nombre" => "Maria del Rosario" "apellidos" => "Muñoz-Ramirez" ] 1 => array:2 [ "nombre" => "Claudia Alejandra" "apellidos" => "Ortega-Valdez" ] 2 => array:2 [ "nombre" => "Eduardo" "apellidos" => "Murillo-Heredia" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "S0025775315004832" "doi" => "10.1016/j.medcli.2015.09.002" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0025775315004832?idApp=UINPBA00004N" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2387020616303370?idApp=UINPBA00004N" "url" => "/23870206/0000014600000009/v1_201609081639/S2387020616303370/v1_201609081639/en/main.assets" ] "en" => array:13 [ "idiomaDefecto" => true "cabecera" => "Scientific letter" "titulo" => "Liraglutide in clinical practice: Glycemic control, and predictors of good response" "tieneTextoCompleto" => true "saludo" => "Dear Editor:" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "415" "paginaFinal" => "416" ] ] "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "Albert Lecube, Cyntia Gonzalez, Cristóbal Morales" "autores" => array:3 [ 0 => array:4 [ "nombre" => "Albert" "apellidos" => "Lecube" "email" => array:1 [ 0 => "alecube@gmial.com" ] "referencia" => array:2 [ 0 => array:2 [ "etiqueta" => "a" "identificador" => "aff0005" ] 1 => array:2 [ "etiqueta" => "*" "identificador" => "cor0005" ] ] ] 1 => array:3 [ "nombre" => "Cyntia" "apellidos" => "Gonzalez" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "b" "identificador" => "aff0010" ] ] ] 2 => array:3 [ "nombre" => "Cristóbal" "apellidos" => "Morales" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "c" "identificador" => "aff0015" ] ] ] ] "afiliaciones" => array:3 [ 0 => array:3 [ "entidad" => "Endocrinology and Nutrition Department, Arnau de Vilanova University Hospital, IRB-Lleida, UdL, Lleida, Spain" "etiqueta" => "a" "identificador" => "aff0005" ] 1 => array:3 [ "entidad" => "Endocrinology and Nutrition Department, Gregorio Marañón University Hospital, Madrid, Spain" "etiqueta" => "b" "identificador" => "aff0010" ] 2 => array:3 [ "entidad" => "Hospital de Día de Diabetes, Unidad de Investigación Clínica, Virgen Macarena University Hospital, UGC Provincial Endocrinologia y Nutrición, Sevilla, Spain" "etiqueta" => "c" "identificador" => "aff0015" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor0005" "etiqueta" => "⁎" "correspondencia" => "Corresponding author." ] ] ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Liraglutide en la práctica clínica: control glucémico y predictores de buena respuesta" ] ] "textoCompleto" => "Type 2 diabetes (T2D) has become epidemic in recent decades and metabolic control has proven unsatisfactory throughout the world. Newly approved drugs have broadened treatment options, yet health care practitioners are increasingly uncertain as to the most suitable approach when treating T2D.<a class="elsevierStyleCrossRef" href="#bib0055">1</a> The first once-daily human GLP-1ra, liraglutide, has proven efficacious in the six LEAD (Liraglutide Effect and Action in Diabetes) clinical trials.<a class="elsevierStyleCrossRefs" href="#bib0060">2,3</a> However, real-life differs markedly from the clinical trial scenery. Therefore, our objective was to retrospectively investigate the effects of liraglutide in two groups of Spanish patients with T2D in a real-life setting. First, we analyzed data from 210 patients with T2D treated with liraglutide at Hospital Universitario Virgen Macarena (Seville, Spain) in order to evaluate changes in weight and HbA1c after 6 months of treatment, as well as the safety of liraglutide. Second, we evaluated baseline characteristics of patients who achieved and maintained HbA1c≤6.5% after 2 years of follow-up. This population comprised 73 consecutive patients who were followed-up at Hospital General Universitario Gregorio Marañón (Madrid, Spain). Inclusion criteria for both studies were: (i) T2D under treatment with metformin; (ii) age≥18 years; (iii) BMI≥30kg/m2; (iv) HbA1c≥7.0%, and (v) glomerular filtration rate≥60ml/min. No pregnant women were included. All participants gave their written informed consent. The initial dose of liraglutide was 0.6mg daily. After 1 week, the dose was titrated to 1.2mg daily, and depending on the metabolic response, to a maximum of 1.8mg.Data from the first population showed that after 6 months of treatment, HbA1c decreased from 8.5±1.7% to 6.4±1.1% (p<0.001), and weight from 106±0.3kg to 99.5±0.5kg (p<0.001), with a total reduction of 7.3kg. The most frequent adverse events were of gastrointestinal origin, leading to withdrawal of treatment in 10.4% of patients. Data from second population showed that, after 2 years of treatment, responders tended to be women (p<0.037), insulin naïve (p<0.048), and did not need insulin during the follow-up (p<0.013).T2DM therapy guidelines include GLP-1ra as one of the six possible options to be added to lifestyle programs and metformin.<a class="elsevierStyleCrossRef" href="#bib0055">1</a> Although these guidelines will undoubtedly expand the range of conditions these drugs are indicated for, data on the effect of liraglutide in other clinical settings are scarce.<a class="elsevierStyleCrossRefs" href="#bib0055">1–3</a> A retrospective analysis performed in the United Kingdom primary care showed that liraglutide was superior to sitagliptin in terms of HbA1c level and weight loss.<a class="elsevierStyleCrossRef" href="#bib0070">4</a> Similar results were obtained in a clinical practice setting when the effectiveness of liraglutide in obese patients was compared with other incretin-based therapies, including exenatide and dipeptidyl peptidase 4 inhibitors.<a class="elsevierStyleCrossRefs" href="#bib0075">5–7</a> A study conducted in the United States on associated economic outcomes in patients with T2D in real-world practice concluded that liraglutide led to significantly greater reductions in HbA1c than sitagliptin without increasing total diabetes-related costs over 6 months of follow-up.<a class="elsevierStyleCrossRef" href="#bib0090">8</a> In this way, data from our first population confirms in Spanish clinical practice what was demonstrated in clinical trials: liraglutide is an optimal approach in obese patients with T2D and leads to significant reductions in both HbA1c and weight.More intriguing is the association between good or poor responses and a specific antidiabetic agent. In the absence of robust pharmacogenetics data, studies performed in real-life scenarios are of major importance when deciding which patients are more likely to respond to liraglutide. We observed that patients who were good responders, defined as an HbA1c≤6.5%, were women who do not combine insulin with liraglutide at baseline or at any other time during the 2-year follow-up. The INITIATOR study also demonstrated that baseline characteristics impact both on the therapeutic option and on clinical outcomes in patients with T2D who initiated injectable therapy (GLP-1ra or insulin glargine): patients receiving liraglutide had fewer comorbidities, lower HbA1c levels, higher weight and were more often women. In addition, patients taking insulin glargine gained weight and experienced more hypoglycemic events after 1 year of treatment.<a class="elsevierStyleCrossRef" href="#bib0095">9</a> Also a French study observed that the 25.5% of patients who achieved a combined objective (HbA1c reduction >1.0% plus weight reduction >3kg after 1 year of treatment) were younger, with a shorter duration of diabetes and higher BMI.<a class="elsevierStyleCrossRef" href="#bib0100">10</a>In conclusion, previous studies on the effectiveness of liraglutide conducted in real life-scenarios in Europe and the USA have shown liraglutide to be superior to exenatide, sitagliptin, and insulin glargine with respect to reductions in HbA1c and weight loss. In addition, some of the predictors of a better response seem to be younger age, shorter duration of T2D, and higher weight at baseline. Based on a population of patients followed for more than 2 years, we extend the list of predictors by adding female gender, insulin naïve, and absence of the need for insulin during follow-up.Financial and competint interest disclosureThis work was supported by Novo Nordisk. The authors have no other relevant affiliations, financial involvement or financial conflict with the subject matter discussed in the manuscrit. The authors take full responsibility for this paper but are grateful to Manuela Rubio for providing writing assistance in the preparation of this manuscript." "textoCompletoSecciones" => array:1 [ "secciones" => array:2 [ 0 => array:2 [ "identificador" => "sec0005" "titulo" => "Financial and competint interest disclosure" ] 1 => array:1 [ "titulo" => "References" ] ] ] "pdfFichero" => "main.pdf" "tienePdf" => true "bibliografia" => array:2 [ "titulo" => "References" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bibs0005" "bibliografiaReferencia" => array:10 [ 0 => array:3 [ "identificador" => "bib0055" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "American Diabetes Association (ADA); European Association for the Study of Diabetes (EASD). Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "S.E. Inzucchi" 1 => "R.M. Bergenstal" 2 => "J.B. Buse" 3 => "M. Diamant" 4 => "E. Ferrannini" 5 => "M. Nauck" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.2337/dc14-2441" "Revista" => array:6 [ "tituloSerie" => "Diabetes Care" "fecha" => "2015" "volumen" => "38" "paginaInicial" => "140" "paginaFinal" => "149" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/25538310" "web" => "Medline" ] ] ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib0060" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The role of GLP-1 mimetics and basal insulin analogues in type 2 diabetes mellitus: guidance from studies of liraglutide" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "A.H. Barnett" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/j.1463-1326.2011.01523.x" "Revista" => array:6 [ "tituloSerie" => "Diabetes Obes Metab" "fecha" => "2012" "volumen" => "14" "paginaInicial" => "304" "paginaFinal" => "314" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/22051096" "web" => "Medline" ] ] ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib0065" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "M. Nauck" 1 => "A. Frid" 2 => "K. Hermansen" 3 => "N.S. Shah" 4 => "T. Tankova" 5 => "I.H. Mitha" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.2337/dc08-1355" "Revista" => array:6 [ "tituloSerie" => "Diabetes Care" "fecha" => "2009" "volumen" => "32" "paginaInicial" => "84" "paginaFinal" => "90" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18931095" "web" => "Medline" ] ] ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bib0070" "etiqueta" => "4" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Evaluation of the effectiveness of liraglutide and sitagliptin in type 2 diabetes: a retrospective study in UK primary care" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "M.E. Nyeland" 1 => "U.J. Ploug" 2 => "A. Richards" 3 => "L. Carcia Alvarez" 4 => "D. Demuth" 5 => "A. Muthutantri" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/ijcp.12575" "Revista" => array:6 [ "tituloSerie" => "Int J Clin Pract" "fecha" => "2015" "volumen" => "69" "paginaInicial" => "281" "paginaFinal" => "289" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/25302822" "web" => "Medline" ] ] ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bib0075" "etiqueta" => "5" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Independent glucose and weight-reducing effects of liraglutide in a real-world population of type 2 diabetic outpatients" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "G.P. Fadini" 1 => "N. Simioni" 2 => "V. Frison" 3 => "M. Dal Pos" 4 => "M. Bettio" 5 => "P. Rocchini" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1007/s00592-013-0489-3" "Revista" => array:6 [ "tituloSerie" => "Acta Diabetol" "fecha" => "2013" "volumen" => "50" "paginaInicial" => "943" "paginaFinal" => "949" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/23754673" "web" => "Medline" ] ] ] ] ] ] ] ] 5 => array:3 [ "identificador" => "bib0080" "etiqueta" => "6" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "A retrospective, case-note survey of type 2 diabetes patients prescribed incretin-based therapies in clinical practice" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "M. Evans" 1 => "P. McEwan" 2 => "R. O'Shea" 3 => "L. George" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1007/s13300-012-0015-6" "Revista" => array:6 [ "tituloSerie" => "Diabetes Ther" "fecha" => "2013" "volumen" => "4" "paginaInicial" => "27" "paginaFinal" => "40" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/23225378" "web" => "Medline" ] ] ] ] ] ] ] ] 6 => array:3 [ "identificador" => "bib0085" "etiqueta" => "7" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "A retrospective audit of type 2 diabetes patients prescribed liraglutide in real-life clinical practice" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "C.M. Mulligan" 1 => "R. Harper" 2 => "J. Harding" 3 => "W. McIlwaine" 4 => "A. Petruckevitch" 5 => "D.M. McLaughlin" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1007/s13300-013-0025-z" "Revista" => array:6 [ "tituloSerie" => "Diabetes Ther" "fecha" => "2013" "volumen" => "4" "paginaInicial" => "147" "paginaFinal" => "151" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/23715814" "web" => "Medline" ] ] ] ] ] ] ] ] 7 => array:3 [ "identificador" => "bib0090" "etiqueta" => "8" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Real-world clinical and economic outcomes of liraglutide versus sitagliptin in patients with type 2 diabetes mellitus in the United States" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "Q. Li" 1 => "A. Chitnis" 2 => "M. Hammer" 3 => "J. Langer" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1007/s13300-014-0084-9" "Revista" => array:6 [ "tituloSerie" => "Diabetes Ther" "fecha" => "2014" "volumen" => "5" "paginaInicial" => "579" "paginaFinal" => "590" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/25256818" "web" => "Medline" ] ] ] ] ] ] ] ] 8 => array:3 [ "identificador" => "bib0095" "etiqueta" => "9" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The INITIATOR Study: pilot data on real-world clinical and economic outcomes in US patients with type 2 diabetes initiating injectable" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "S. Thayer" 1 => "W. Wei" 2 => "E. Buysman" 3 => "L. Brekke" 4 => "W. Crown" 5 => "M. Grabner" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1007/s12325-013-0074-8" "Revista" => array:6 [ "tituloSerie" => "Therapy Adv Ther" "fecha" => "2013" "volumen" => "30" "paginaInicial" => "1128" "paginaFinal" => "1140" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24293131" "web" => "Medline" ] ] ] ] ] ] ] ] 9 => array:3 [ "identificador" => "bib0100" "etiqueta" => "10" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Predictive criteria for clinical response to liraglutide: results from a “real life” study" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "O. Dupuy" 1 => "L. Bordier" 2 => "C. Garcia" 3 => "A. Brinkane" 4 => "B. Lormeau" 5 => "M. Popelier" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Med Malad Metab" "fecha" => "2014" "volumen" => "1" "paginaInicial" => "56" "paginaFinal" => "60" ] ] ] ] ] ] ] ] ] ] ] "idiomaDefecto" => "en" "url" => "/23870206/0000014600000009/v1_201609081639/S2387020616303357/v1_201609081639/en/main.assets" "Apartado" => array:4 [ "identificador" => "43311" "tipo" => "SECCION" "en" => array:2 [ "titulo" => "Scientific letters" "idiomaDefecto" => true ] "idiomaDefecto" => "en" ] "PDF" => "https://static.elsevier.es/multimedia/23870206/0000014600000009/v1_201609081639/S2387020616303357/v1_201609081639/en/main.pdf?idApp=UINPBA00004N&text.app=https://www.elsevier.es/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2387020616303357?idApp=UINPBA00004N"]

ISSN: 2387-0206

Launched in 1943, Medicina Clínica is a fortnightly journal aimed at the promotion of clinical research and practice among internal medicine and other specialists. The key characteristics of Medicina Clínica are the scientific and methodological rigor of its manuscripts, the topicality of its contents, and, especially, its practical focus with highly useful information for clinical practice. Medicina Clínica is predominantly interested in publishing original research manuscripts, which are rigorously selected according to their quality, originality, and interest, and also in continued medical education-oriented manuscripts, which are commissioned by the journal to relevant authors (Editorials, Reviews, and Diagnosis and Treatment). These manuscripts contain updated topics with a major clinical or conceptual relevance in modern medicine. The journal adheres to the standards of academic research publications in all aspects including peer-review and ethical principles. Medicina Clínica is included in the General and Internal Medicine category of Thomson Reuters.

See more Open Access Option

Indexed in:

Current Contents/Clinical Medicine, Journal Citation Reports, SCI-Expanded, Index Medicus/Medline, Excerpta Medica/EMBASE, IBECS, IME, MEDES, PASCAL, SCOPUS, SciVerse ScienceDirect

Subscribe:

Impact factor

The Impact Factor measures the average number of citations received in a particular year by papers published in the journal during the two preceding years.

© Clarivate Analytics, Journal Citation Reports 2022

Impact factor 2023

2.6

Citescore

CiteScore measures average citations received per document published.

Citescore 2023

3.1

SJR

SRJ is a prestige metric based on the idea that not all citations are the same. SJR uses a similar algorithm as the Google page rank; it provides a quantitative and qualitative measure of the journal's impact.

SJR 2023

0.371

SNIP

SNIP measures contextual citation impact by wighting citations based on the total number of citations in a subject field.

SNIP 2023

0.511

View more metrics

Journal Information

Previous article | Next article

Vol. 146. Issue 9.

Pages 415-416 (May 2016)

Export reference

Download PDF

Article

These are the options to access the full texts of the publication Medicina Clínica (English Edition)

Subscriber

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”

Subscribe to

Medicina Clínica (English Edition)

More information

Purchase

Purchase article

Purchasing article the PDF version will be downloaded

Price 19.34 €

Purchase now

Contact

Phone for subscriptions and reporting of errors

From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.

Calls from Spain

932 415 960

Calls from outside Spain

+34 932 415 960

E-mail

atencionalcliente@elsevier.com

Publish in

Medicina Clínica

Tools

Indexed in:

Follow us:

Subscribe:

Article

Subscribe to our newsletter